Psyence Biomedical (PBM) stock rallied 42% on Friday, on track for its best week in over two years. The surge follows reports that White House is drafting an executive order to research psychedelics. CEO Jody Aufrichtig welcomed efforts to advance evidence-based research, highlighting increasing global interest. Psyence also highlighted its investment in Psylabs for sustainable ibogaine sourcing.